Medpace (NASDAQ:MEDP) Updates FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 16.680-17.500 for the period, compared to the consensus earnings per share estimate of 17.230. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Medpace Trading Down 1.3%

Shares of MEDP stock traded down $6.44 during trading hours on Wednesday, hitting $508.46. The company’s stock had a trading volume of 398,616 shares, compared to its average volume of 342,794. The company has a 50 day moving average of $469.72 and a 200 day moving average of $537.76. The stock has a market cap of $14.52 billion, a PE ratio of 33.23, a price-to-earnings-growth ratio of 2.49 and a beta of 1.39. Medpace has a 12-month low of $282.84 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts anticipate that Medpace will post 17.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Truist Financial reduced their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research report on Friday, February 13th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and reduced their price objective for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $486.67.

Insider Transactions at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Zacks highlights Medpace’s growth attributes — strong revenue and earnings growth, high ROE, and long-term pipeline potential — arguing MEDP remains a solid growth stock that could deliver exceptional returns if execution continues. Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think “Yes”
• Neutral Sentiment: Cincinnati plans a bike path near Medpace’s Madisonville headquarters — a local infrastructure project with limited direct financial impact but positive for community relations and employee access. Cincinnati to build bike path near headquarters of one of region’s largest companies
• Neutral Sentiment: Market previews and analyst notes ahead of Medpace’s Q1 report could drive volatility around the print; investors should watch guidance commentary vs. expectations. Medpace (MEDP) Q1 Earnings: What To Expect
• Negative Sentiment: Multiple law firms have filed claims or are soliciting lead plaintiffs in a securities class action alleging Medpace overstated growth projections and harmed investors (class period: April 22, 2025 — February 9, 2026). Firms are urging investors to seek lead‑plaintiff status before a June 8, 2026 deadline — the surge of notices increases legal overhang and headline risk that likely pressured the stock. Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Quarry LP acquired a new position in Medpace during the third quarter worth $35,000. Greenline Wealth Management LLC acquired a new position in Medpace during the fourth quarter worth $55,000. Group One Trading LLC lifted its stake in Medpace by 120.0% during the fourth quarter. Group One Trading LLC now owns 100 shares of the company’s stock worth $56,000 after purchasing an additional 600 shares in the last quarter. Finally, Johnson Financial Group Inc. lifted its stake in Medpace by 115.7% during the third quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock worth $57,000 after purchasing an additional 59 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.